PredictAD

Dementia causes long and oppressive suffering to patients and their relatives and imposes enormous costs on society. About 25 million people suffered from dementia in 2000. As a 4-fold increase of this number is expected by 2050, dementia is one main health issue of the next decades.

Alzheimer's disease (AD) covers 60-70% of all dementia cases. No cure for AD exists, and effective and reliable early diagnostic techniques are lacking. Early diagnosis and progress monitoring of AD is a central part of treatment once future drugs and prevention strategies become available. There is a strong indication that different biomarkers provide a reliable and early indication of AD prior to its major clinical signs. However, optimal early diagnosis requires information from a combination of different biomarkers to be used in a clinically useful way.

The objective of PredictAD is 1) to find the best combination of biomarkers for AD diagnostics from heterogeneous data (imaging, electrophysiology, molecular level, clinical tests, demographics) and 2) to develop clinically useful tools integrating the optimal biomarker results. Comprehensive biomarker discovery techniques and rigorous statistical models will be developed using the consortium's large databases. The accuracy and usability of models and tool will be clinically evaluated. The cost-effectiveness of heterogeneous data in AD diagnostic procedures will be studied.

By reaching its objectives, PredictAD provides an efficient and reliable solution for early AD diagnosis in clinical practice. The impacts on patients, their relatives and society are reduced suffering and costs. As we are living in the dawn of an era of new drugs and prevention strategies combined with increasing AD prevalence, now is the time to exploit the vast potential of information hiding in heterogeneous patient databases. PredictAD combines the best forces in Europe to solve the AD diagnostics problem, and hence strengthens EU leadership on the market.

For further information, please visit:
http://www.predictad.eu

Project co-ordinator:
Valtion teknillinen tutkimuskeskus VTT

Partners:

  • Nexstim Oy
  • Imperial College of Science, Technology and Medicine
  • Rigshospitalet
  • Kuopion yliopisto
  • Università degli Studi di Milano
  • GE Healthcare Ltd.
  • Uppsala universitet

Timetable: from 06/2008 – to 05/2011

Total cost: € 3.981.565

EC funding: € 2.891.526

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Doctors Rely on More than Just Data for …

Many technology companies are working on artificial intelligence systems that can analyze medical data to help diagnose or treat health problems. Such systems raise the question of whether this kind...

App, Brief Intervention may be Lifesaver…

A troubled teenager is hospitalized with suicidal thoughts. The patient is diagnosed, medicated, and counseled by a team of experts. The teen is sent home a few days later, and...

New Coalition of Philanthropists Includi…

Philanthropist Bill Gates and the Alzheimer's Drug Discovery Foundation (ADDF) co-founder Leonard Lauder have announced a new initiative, Diagnostics Accelerator, to develop novel biomarkers for the early detection of Alzheimer's...

IMI Launches New Antimicrobial Resistanc…

A new Antimicrobial Resistance (AMR) Accelerator Programme is part of new Calls for proposals launched today by the Innovative Medicines Initiative (IMI). Of the other topics launched in the Calls...

Wearable Devices and Mobile Health Techn…

With increasing efforts being made to address the current global obesity epidemic, wearable devices and mobile health ("mHealth") technology have emerged as promising tools for promoting physical activity. However, current...

Frontiers Health 2018

15 - 16 November 2018, Berlin, Germany. Frontiers Health has fast become one of the premiere conferences in the digital health space, combining a unique mix of attendees and presenters from...

Digital Health to Disrupt Health IT Mark…

25 - 26 March 2019, London, United Kingdom. Digital Health - publishers of digitalhealth.net and organisers of the CCIO, CNIO, CIO Networks and annual Summer Schools - is to shake up...

Bayer Cares Foundation Promotes Sustaina…

Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim...

Philips and Oxford University Hospitals …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Oxford University Hospitals (OUH) NHS Foundation Trust, announced plans to create a digital pathology network to help...

Maidstone and Tunbridge Wells NHS Trust …

Maidstone and Tunbridge Wells NHS Trust has selected Allscripts Sunrise as its electronic health record, in a move that further solidifies the company's position in the South East of England...

Start Alliance Berlin: Digital Health

Start Alliance Berlin: Digital Health is a two-week program taking place in November 2018 which is intended to help startups from BEIJING, DUBAI, NEW YORK, LONDON, PARIS, SHANGHAI, TEL AVIV...